Erleada (Titan)
Support
Resources
Analytics
Nubeqa
100

Median OS in both arm

What is NR vs 52.2 months (HR: 0.65) 35% red

100

HCP and Patient support

What is CarePath

100

A popular subscription service for Prostate Cancer

  • What is URO Today?
100
  • Based on claims data

What is Scalpel?

100
  • A new standard of care in mHSPC or mCSPC

 What is Nubeqa Triplet Therapy (Darolutamide 600mg + ADT + Docetaxel)?

200

Median rPFS in both arms

What is NR vs 22.1 months (HR: 0.48)

200

One on one patient navigation offering Cost, Access, Treatment Education and support

  • What is Care Compass
200

An online “University” with info on Prostate Cancer … and everything else

What is You Tube?

200
  • Decommissioned on September 6, 2022 

What is IQLIK?

200
  • Dosage

What is 600 mg (2 300 mg tablets) BID with food

300

Dosage

What is 240 mg (2 60 mg tablets) QD with or without food ; with alternative dosing options for difficulty swallowing

300

You get $15,000 annually

What is Co-Pay program?

300

An app that was recently recommended that replays the next day, hosted by NYU

What is Doctor Radio on Sirius XM channel 110?

300
  • Optional office hours scheduled thru Sept 5

 What is WIZARD?

300
  • The % Grade ¾ AEs in ARASENS 

What is 66.1% vs 63.5%?

400

% high volume disease patients included in trial

  • what is 62.7%?
400

Can educate staff and see patient specific payor information

  • Who is the FRAS?
400

An app to find people and thoughts

What is Twitter?

400
  • $$$ 

What is IC compensation

400

The primary endpoint of ARASENS trial

What is median OS of 48.9 months (vs NE) 32.5% reduction , HR: 0.675?

500

% Advantaged Coverage for commercial and medicare pts vs Xtandi

what is 97% vs 87%

500

Shows Rejections and Abandoned RX

  • What is Scalpel
500

An app recommendation for Prostate Cancer Update

  • What is Prostate Cancer Update Podcast?
500
  • How are you ranked

 What is presidents circle ranking?

500

4 year rate of OS in both arms of ARASENS trial

What is 62.7 vs 50.4%

M
e
n
u